Document Type : Original Article


Department of Neurology, Khoula Hospital, Muscat, Oman


Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated condition with variable clinical characteristics and different treatment modalities. We aim to present different clinical and demographic features of all patients with CIDP presented to the neuromuscular clinic within four years and their follow-up results.
Methods: A retrospective study from a hospital database of 23 patients met the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIPD. Complete demographic and clinical data were collected. Progress and outcome were assessed using two clinical score systems at regular intervals at 6, 12, and 18 months.
Results: Mean age of patients was 43.4 ± 20.9 years (male-to-female ratio was 1.6:1). Age of onset was 39.7 ± 18.0 years. At the presentation, the Medical Research Council sum score (MRCss) was 50 (39.7-51.3), and the modified Rankin Scale (mRS) was 3 (2.2-3.4). There was a significant improvement in MRCss during four periods (P < 0.001). Multiple comparisons revealed a significant difference in MRCss between the baseline and 12 and 18 months but no significant change between the baseline and 6 months. Likewise, mRS showed a significant improvement between the baseline and 18 months (no significant change between the baseline and 6 months or 12 months).
Conclusion: The clinical characteristics of CIDP in our cohort were similar to other reported studies, and most of the studied patients had good outcomes. Our results could be utilized as baseline data for a better understanding of the characteristics of CIDP in Oman and, consequently, for better management of the disease.


  1. Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 2015; 85(6): 498-504.
  2. Reynolds J, Sachs G, Stavros K. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Clinical features, diagnosis, and current treatment strategies. R I Med J (2013) 2016; 99(12): 32-5.
  3. Spina E, Topa A, Iodice R, Tozza S, Ruggiero L, Dubbioso R, et al. Early predictive factors of disability in CIDP. J Neurol 2017; 264(9): 1939-44.
  4. Bourque PR, Brooks J, Warman-Chardon J, Breiner A. Cerebrospinal fluid total protein in Guillain-Barre syndrome variants: Correlations with clinical category, severity, and electrophysiology. J Neurol 2020; 267(3): 746-51.
  5. Rajabally YA, Stettner M, Kieseier BC, Hartung HP, Malik RA. CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nat Rev Neurol 2017; 13(10): 599-611.
  6. Allen JA, Lewis RA. Diagnosis of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2022; 66(5): 545-51.
  7. Hiew FL, Ong JJ, Viswanathan S, Puvanarajah S. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. J Clin Neurosci 2018; 50: 203-7.
  8. Rajabally YA, Fatehi F. Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice. Neurodegener Dis Manag 2019; 9(5): 259-66.
  9. Rentzos M, Anyfanti C, Kaponi A, Pandis D, Ioannou M, Vassilopoulos D. Chronic inflammatory demyelinating polyneuropathy: A 6-year retrospective clinical study of a hospital-based population. J Clin Neurosci 2007; 14(3): 229-35.
  10. Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184(1): 57-63.
  11. Laughlin RS, Dyck PJ, Melton LJ, III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73(1): 39-45.
  12. Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79(9): 1040-3.
  13. Kandil MR, Darwish ES, Khedr EM, Sabry MM, Abdulah MA. A community-based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res 2012; 34(10): 960-6.
  14. Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol 2003; 60(2): 260-4.
  15. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK population. Muscle Nerve 2009; 39(4): 432-8.
  16. Chio A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: An epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78(12): 1349-53.
  17. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21(1): 28-33.
  18. Abraham A, Albulaihe H, Alabdali M, Qrimli M, Breiner A, Barnett C, et al. Frequent laboratory abnormalities in CIDP patients. Muscle Nerve 2016; 53(6): 862-5.
  19. Okhovat AA, Gholamalizadeh S, Nafissi S, Fatehi F. Evaluation of quality of life in patients with chronic inflammatory demyelinating polyneuropathy in Iran. J Clin Neuromuscul Dis 2019; 21(2): 77-83.
  20. Molenaar DS, Vermeulen M, de Haan RJ. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol 2002; 249(4): 400-3.
  21. Pitarokoili K, Schlamann M, Kerasnoudis A, Gold R, Yoon MS. Comparison of clinical, electrophysiological, sonographic and MRI features in CIDP. J Neurol Sci 2015; 357(1-2): 198-203.
  22. Rajabally YA, Narasimhan M. Characteristics and correlates of sensory function in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2010; 297(1-2): 11-4.
  23. Alabdali M, Abraham A, Alsulaiman A, Breiner A, Barnett C, Katzberg HD, et al. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. J Neurol Sci 2017; 372: 223-7.
  24. Mori K, Hattori N, Sugiura M, Koike H, Misu K, Ichimura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002; 58(6): 979-82.
  25. Kuitwaard K, van der Pol WL, Ruts L, van Doorn PA. Individual patients who experienced both Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2009; 14(1): 66-8.
  26. Panaite PA, Renaud S, Kraftsik R, Steck AJ, Kuntzer T. Impairment and disability in 20 CIDP patients according to disease activity status. J Peripher Nerv Syst 2013; 18(3): 241-6.